CTLA4 and hepatocellular carcinoma: For HCC patients with both CTLA4 and PD-1 double-positive or double-negative, or PD-1 positive but CTLA4 negative, the IPS of patients in the high-risk group was noticeably lower than that of the low-risk group, that is, under the above-mentioned conditions, patients in the former had a worse effect on immunotherapy (Figure 11A–11C).